Metal (II) Complexes of Fluconazole: Thermal, XRD and Cytotoxicity Studies

authors:

avatar Syed Imran Ali a , * , avatar Zi-Ning Lei b , avatar Mohsin Ali c , avatar Konatsu Kojima b , avatar Mansoor Ahmed d , avatar Richard Peng b , avatar Dong-Hua Yang b , avatar Syed Moazzam Haider e , avatar Seyed Abdulmajid Ayatollahi f , g , avatar Zhe-Sheng Chen b

Department of Applied Chemistry and Chemical Technology, Faculty of Science, University of Karachi, Karachi-75270, Pakistan.
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA.
Department of Chemistry, Faculty of Science, University of Karachi, Karachi-75270, Pakistan.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Karachi, Karachi-75270, Pakistan.
Industrial Analytical Center (ICCBS), University of Karachi, Karachi-75270, Pakistan.
Phytochemistry Research Center, Shahid Beheshti Univercity of Medical Sciences, Tehran, Iran.
Department of Pharmacognosy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iranian Journal of Pharmaceutical Research : IJPR: Vol.19, issue 3; 171-182
article type: Original Article
received: July , 2017
accepted: December , 2018
DOI: https://doi.org/10.22037/ijpr.2020.1101142

how to cite: Ali S I, Lei Z, Ali M, Kojima K, Ahmed M, et al. Metal (II) Complexes of Fluconazole: Thermal, XRD and Cytotoxicity Studies. Iran J Pharm Res. 2020;19(3):e124396. https://doi.org/10.22037/ijpr.2020.1101142.

Abstract

We report thermal, X-ray diffraction (XRD) and cytotoxicity studies of complexes of fluconazole (FCZ) with Cu (II), Fe(II), Cd(II), Co(II), Ni(II), and Mn(II). From XRD measurements, FCZ and its metal complexes were identified as polycrystalline. Marked differences in the X-ray patterns of drug and its metal complexes revealed that the complexes are indeed different compounds and not just the mixture of the starting materials. Unlike pristine FCZ, which did not exhibit cytotoxicity, three complexes derived from Fe(II), Cu(II) and Co (II) proved to be effective in the cytotoxicity assay. The Cu(II)-FCZ exhibited significant activity against SNB-19, HCT-15, COLO-205, and KB-3-1 cell lines, while Fe(II)-FCZ and Co(II)-FCZ were found cytotoxic only to KB-3-1 cell line. For the pure FCZ, thermogravimetry revealed massive weight loss in the temperature range of 215 to 297 °C, due to the volatilization of FCZ. All the complexes followed multi-stage degradation profiles, eventually resulting in the formation of metal oxides. For pure FCZ, differential scanning calorimetry revealed melting point at 137 °C, followed by two further endothermic transitions at 294 °C and 498.44 °C representing the volatilization and subsequent degradation of FCZ, respectively. The absence of endothermic FCZ melting peak at around 137 °C indicates that the complexes represent different compounds. All complexes exhibit endothermic transitions at around 240-300 °C, representing melting and removal of ligand moiety, followed by another endothermic transition at around 498-499 °C, representing the ligand decomposition.

Introduction

Over the last few decades, growing resistance of microorganisms against existing drugs have been a significant concern for researchers as it poses a considerable burden on the health departments of nations around the world (1-3). Substantial increase has been observed in the population of patients suffering from fungal infections, particularly infecting immune compromised patients, such as those infected with HIV/AIDS, or with a neoplastic condition, transplant recipients, patients under treatment in intensive care units and those which are undergoing chemotherapies (4-13). The growing trend in the population of patients at risk posed a serious challenge to the medical community and triggered the endeavors to explore new strategies to improve efficiency and efficacy of existing antifungals (5, 6).

Among the antifungals introduced in clinical practice, fluconazole (FCZ) remains the most widely explored owing to many advantages it offers (6, 14). Due to its excellent antifungal activity coupled with low toxicity, excellent pharmacokinetics and bioavailability, FCZ was considered to be the standard treatment against various fungal infections for many years since it became available for clinicians in 1990s (6, 15-18). The hydro-soluble nature renders it suitable for intravenous admiration (6). Besides, it demonstrated excellent gastrointestinal absorption and spread easily by diffusion throughout the entire body, including cerebrospinal fluid (19, 20). For treating fungal infections in human, FCZ has demonstrated significantly better clinical and mycological cure rate compared to itraconazole in oropharyngeal candidiasis (21). Oral suspensions of FCZ are widely used in oral pseudomembranous candidiasis because of its good adhesion to the surface of the oral mucosa and a rapid symptomatic response (22-26). Its efficacy has also been demonstrated in immune compromised patients, such as those which are HIV-infected, or with a neoplastic condition (21, 27 and 28). FCZ also exhibits the activity against Candida lusitaniae. For patients suffering from candidial osteomyelitis who are unable to start or complete the required course of amphotericin B, FCZ is a reasonable alternative and has been successful in achieving desired treatment results (29, 30).

Despite the set of favorable properties it offers, FCZ is still not considered as the perfect antifungal and has certain drawbacks which needs to be overcome. For instance, just like the other members of Azole family of antifungals, it has some non-negligible interactions with certain drugs which can cause a decrease in drug concentration or, to some extent, an increased toxicity (31). Besides, its ineffectiveness against emerging pathogens such as Scedosporium, Fusarium, and Mucorales has also been reported (32). Since its emergence in the market, FCZ simulated extensive use against various fungal infections and chemoprophylaxis (33-35). Afterwards, over-prescription by physicians led to an increase in resistance to FCZ in a high percentage of patients (15, 36-39). Well established clinical and commercial importance highlights the need to explore new strategies and formulations to improve efficiency and efficacy of FCZ.

During the past decade, synergic effect of metal ions on the activity and efficacy of various drugs has been reported in several research papers. Drug-metal ion complexes have proven their efficacy in various fields of health such as anticancer chemotherapeutic agents, antacids, and anti-rheumatics (40, 41). With the aim to improve efficiency and efficacy of FCZ, we recently started research work to explore the synthesis of metal complexes of FCZ. A series of complexes of fluconazole with Cu (II), Fe(II), Cd(II), Co(II), Ni(II) and Mn(II) were synthesized and the morphological, spectroscopic, and antifungal properties were thoroughly reported (40). In this contribution, we further extend our previous study on these complexes to explore their thermal, X-ray diffraction, and cytotoxicity properties.

Experimental

Materials

The fluconazole (FCZ) sample was kindly provided by NabiQasim Pharma (PVT) Ltd, Karachi, Pakistan. Hydrated chlorides of copper, iron, manganese, cadmium, cobalt, and nickel (Merck, Germany) were all used as received. Methanol (analytical grade, Merck, Germany) was used as received. For all experiments, freshly distilled water was used.

Synthesis of the Complexes

A series of metal complexes of FCZ with Co, Mn, Fe, Ni, Cu, and Cd were synthesized. Details of the synthesis procedure and characterizations of the resulting complexes have already been described in our previous paper (40). A general synthesis scheme is depicted in Scheme 1.

Characterization

X-ray diffraction studies were performed to explore the crystallinity of fluconazole and its metal complexes using a Bruker AXS D8 (Germany) X-Ray diffractometer operated at 40 kV and 60 mA and equipped with a Cu-Kα1 radiation (1.54 Å). The data were recorded at a scanning speed of 5◦/min in the range of 10° < 2θ < 60° using a step size of 0.02°/point. All samples were analyzed as dry powder.

Thermal properties of complexes were studied using differential scanning calorimetry (DSC) performed on a TA Instruments STD Q600 system under nitrogen atmosphere (50 kPa pressure). For all measurements, around 10 to 12 mg of powder samples, enclosed in DSC pans, were heated from room temperature to 700 °C at a scan rate of 10 °C min-1. The parameters, such as onset temperature and peak temperature, were recorded from heating scans. Thermogravimetric analysis (TGA) was performed on a TA Instruments STD Q600 system using approximately 10 to 12 mg samples placed in crucibles. The samples were heated from room temperature to 700 °C at a heating rate of 10 °C min-1 in nitrogen atmosphere.

Four cell lines including human astrocytoma SNB-19, human Dukes’ type C colorectal adenocarcinoma HCT-15, human Dukes’ type D colorectal adenocarcinoma COLO-205, and human epidermoid carcinoma KB-3-1 were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The cell lines were grown in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin in a humidified incubator at 37 °C with 5% CO2.

MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay was used to evaluate the cytotoxicity of the test compounds. The cells were inoculated in 96-well plates at the density of 5,000 cells per well and allowed to adhere and grow for 24 h. The test compounds in different concentration were incubated with the cells for 72 h. After drug incubation, 4 mg/mL MTT solution was added to the cells by 20 μL per well followed by a four-hour incubation. The cell viability was measured by reduction of the yellow dye MTT to a blue formazan product that were dissolved in DMSO (42). The absorbance of the blue dissolved formazan crystals in the viable cells was measured at 570 nm by using accuSkan™ GO UV/Vis Microplate Spectrophotometer (Fisher Sci., Fair Lawn, NJ). The IC50 values (50% inhibitory concentration) were calculated.

Results and Discussion

X-Ray Diffraction

To explore the structure of the FCZ and its metal complexes, X-ray diffraction technique was used. The resulting X-ray patterns of pure FCZ and its metal complexes are shown in Figure 1. For the pure FCZ sample (Figure 1a), prominent diffraction peaks in the range of 2θ = 10–60ᵒ are evident clearly indicating a polycrystalline nature. It has been reported earlier that FCZ existed in at least two polymorphic forms which exhibit granular and flake-like slabs morphologies. The observed pattern agrees fairly well with that reported by Satish et al., although there are few more spikes, which are likely due to the presence of more than one polymorphic form (42, 43). Consequently, the raw FCZ was identified as a mixture of polymorphs.

The diffractograms obtained for the metal complexes Co(II)-FCZ, Cu(II)-FCZ, Fe(II)-FCZ, Mn(II)-FCZ, and Ni(II)-FCZ are depicted in Figures 1b-1f, respectively. By comparing the obtained X-ray powder diffraction patterns given in Figure 1, it can be easily seen that the pattern obtained for the pure FCZ sample (Figure 1a) differs drastically from those obtained for all its metal complexes. Thus, it can be inferred that each complex represents a definite compound of a definite structure and not merely the mixture of the starting materials (44). Besides, all complexes exhibited diffraction peaks at various angles with a lower intensity compared to the pure drug showing their crystalline nature with smaller particle sizes.

Thermal Stability

Thermal stabilities of FCZ and its metal complexes were explored using thermogravimetric analysis (TGA) which was performed on powder samples under inert atmosphere employing a heating rate of 10 °C min-1. The resulting thermograms are shown in Figure 2. For the pristine drug sample, a weight loss of around 1.8% was observed before the melting temperature in the range of 65–110 °C, which corresponds to the loss of water content. Considering the molecular weights of water and FCZ, and the percent weight loss, it can be inferred that the raw FCZ employed in this study is likely a mixture of different polymorphs and not solely consist of a monohydrate (45, 46). This result is consistent with the XRD findings which also revealed the presence of more than one polymorphic form.

Upon further heating, FCZ undergoes a melting transition at around 135 to 138 °C. The drug then remained stable up to 215°C until a massive weight of around 99% was observed in the temperature range of 215 to 297 °C. The observed massive weight loss, as previously reported by Moura et al. is attributed to the volatilization of molecular FCZ (47). The thermogravimetric analysis were also performed for Cd (II)-FCZ, Co (II)-FCZ, Cu(II)-FCZ, Fe (II)-FCZ, Mn(II)-FCZ, and Ni (II)-FCZ complexes and the results are presented in Figures 2b-2g. As was expected, the decomposition of all the complexes eventually resulted in the formation of metal oxide which demonstrates stability throughout the temperature range explored. All complexes exhibit multi stage degradation profiles which started with the initial loss of water molecules followed by losses of ligand molecules. Remarkably, compared to pure FCZ, the complexes exhibit better thermal stability and resulted in a substantial residual mass even after heating to 700 °C.

Differential Scanning Calorimetry (DSC)

The DSC patterns recorded for FCZ and its complexes are shown in Figure 3. An endothermic peak located at around 100 °C in the calorimetric curve of FCZ (Figure 3a) corresponds to the dehydration process. As the melting points of the three known polymorphic forms of FCZ have been reported to fall in the range of 135 to 140 °C, the endothermic transition detected at 137 °C is clearly representing the melting transition (47, 48). Endothermic transition observed beyond melting likely corresponds to the volatilization of molecular FCZ at 294 °C and its subsequent degradation at 498.44 °C (47). The calorimetric curves were also recorded for all the six complexes (Cd (II)-FCZ, Co (II)-FCZ, Cu (II)-FCZ, Fe (II)-FCZ, Mn (II)-FCZ, and Ni (II)-FCZ). For all the complexes explored, the observed endothermic transitions in the temperature range of 30 to 70 °C correspond to the loss of water molecules from the crystals (49, 50). A striking feature of the calorimetric curves of the complexes is the absence of endothermic melting peak of pure FCZ which indicates that these complexes represent definite compounds and are not merely the mixture of the starting materials. Further, endothermic peaks representing the melting and subsequent removal of ligand moiety occurred for Cd (II)-FCZ at 246.67 °C, Co (II)-FCZ at 261.44 °C, Cu (II)-FCZ at 170 °C and 222.88 °C, Fe (II)-FCZ at 264.34 °C, Mn (II)-FCZ at 290.77 °C and Ni (II)-FCZ at 308.43 °C. In case of all the complexes, endothermic transitions occurred at around 498-499 °C corresponding to the decomposition of ligand after which the complexes exhibit gradual decomposition up to 700 °C.

Anticancer Activity

The IC50 values of the FCZ and its metal complexes on the human cancer cells used were summarized in Table 1. For the two types of human colorectal adenocarcinoma cells HCT-15 and COLO-205 cells, only Cu(II)-FCZ had slight cytotoxic effects, with similar IC50 values (mean ± standard deviation) of 60.10 ±7.85 μM, and 60.90 ± 4.58 µM, respectively. Also, only Cu(II)-FCZ had mild cytotoxicity on SNB-19 cells, but with a relatively lower IC50 value of 27.80 ± 4.16 µM. KB-3-1 cells exhibited higher sensitivity to the drugs than the other three cell lines. Among the seven compounds, Fe(II)-FCZ, Cu(II)-FCZ, and Co(II)-FCZ had IC50 values lower than 100 µM on KB-3-1 cell line, which were 81.33 ± 11.35 µM, 13.04 ± 5.72 µM, and 62.03 ± 19.84 µM, respectively (Figure 4).

The results reflected that metal cations, in the form of drug complexes with organic ligand, act as a critical role in anticancer activity. Previous study showed that the complexes are able to stabilize the cleavable complex formed between enzyme and DNA, meanwhile control the replication and transcription of DNA in malignant tumour cells (44). Therefore, a complex with cation metal would show more active anticancer efficiency than the ligand alone. In this study, we also observed enhanced cytotoxic effects of metal complex than the parent compound FCZ on cancer cell lines. The mechanism may be related to the charge of metal and the high reactivity of the complex due to unpaired electrons, which may lead to superoxide dismutase (SOD) mimic activity and DNA cleavage activity that further results in cell apoptosis (51). This has been proved by the previous study with other azole compounds and metal complexes.

For example, a recent research showed that benzotriazole based Fe(III)-salen-like complex displayed remarkable anticancer activity against human chronic myelogenouserythroleukemia cell line and breast adenocarcinoma cell line, and further mechanistic studies supported that the resulting cancer cell apoptosis was probably led by certain superoxide dismutase (SOD) mimic activity and the subsequent local imbalance in superoxide/hydrogen peroxide levels(48). However, in our observation, not all metal complexes had significant anticancer effects, and a complex may not show cytotoxicity on all cancer cell lines, indicating that different metals may have different mechanisms of effects, which requires more researches in the future to uncover other findings.

Synthesis of metal complexes of fluconazole (FCZ)

Synthesis of metal complexes of fluconazole (FCZ)

Scheme 1

Table 1

Cytotoxicity of FCZ and metal complexes of FCZ on four human cancer cell lines

DrugIC50 ± SD (μM)
SNB-19HCT-15COLO-205KB-3-1
FCZ>100>100>100>100
Fe(II)-FCZ>100>100>10081.33 ± 11.35
Cu(II)-FCZ27.80 ± 4.1660.10 ± 7.8560.90 ± 4.5813.04 ± 5.72
Ni(II)-FCZ>100>100>100>100
Mn(II)-FCZ>100>100>100>100
Cd(II)-FCZ>100>100>100>100
Co(II)-FCZ>100>100>10062.03 ± 19.84

Conclusion

Clinical and commercial importance of fluconazole (FCZ) has become an inspiration for researchers to explore new strategies and formulations to improve its growing ineffectiveness as antifungal. Complexation of drugs with metal ions is a well-established approach in medicinal chemistry to improve the efficacy of various drugs. The present contribution was intended to explore six complexes of FCZ with Cu (II), Fe(II), Cd(II), Co(II), Ni(II), and Mn(II) for their thermal, XRD, and cytotoxicity properties.

Our results revealed that pure FCZ and its metal complexes were of polycrystalline nature. Contrary to the pure FCZ, three complexes demonstrated cytotoxicity against four human cancer cell lines used in the cytotoxicity assay. The Cu (II)-FCZ complex had cytotoxic activity against all four cancer cells, while Fe (II) and Co (II) complexes of FCZ showed some cytotoxic activity against KB-3-1 cancer cell, which implied the important role of metal complexes in anticancer activity. In case of pure FCZ, thermogravimetry revealed massive weight loss in the temperature range of 215 to 297 °C, due to the FCZ volatilization. The complexes; however followed multi stage degradation profiles, eventually resulting in the formation of metal oxides. From differential scanning calorimetry, the melting transition for pure FCZ was identified at 137 °C. Remarkably, this transition was not observed for all the six complexes indicating that these complexes represent definite compounds. Additional endothermic transitions for pure FCZ and its metal complexes were also observed.

Although not all metal complexes showed effectiveness, the obtained results indicate activity of Cu (II)-FCZ, Fe (II)-FCZ, and Co (II)-FCZ for the chosen strains. It can be said that the FCZ metal complexes embody a starting point towards the development and optimization of more effective anticancer and antifungal drugs and will likely lead to new direction for studies of novel antifungal formulations. More studies on evaluation of these metal complexes and further preparation of different derivatives are needed.

Acknowledgements

References

  • 1.

    Berber I, Cokmus C, Atalan E. Characterization of Staphylococcus species bySDS–PAGE of whole-cell and extracellular proteins. Microbiology. 2003;72:42-7.

  • 2.

    Harbarth S, Albrich W, Goldmann DA, Huebner J. Control of multiply resistant cocci: do international comparisons help? Lancet Infect. Dis. 2001;1:251-61.

  • 3.

    Mitscher LA, Pillai SP, Gentry EJ, Shankel DM. Multiple drug resistance. Medicinal Res. Rev. 1999;19:477-96.

  • 4.

    Pfaller M, Diekema D. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 2007;20:133-63. [PubMed ID: 17223626].

  • 5.

    Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. BioMed. Res. Int. 2013;2013:1-13.

  • 6.

    Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int. J. Microbiol. 2011;2012:1-26.

  • 7.

    Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 1997;24:1122-8. [PubMed ID: 9195068].

  • 8.

    Ables AZ, Blumer NA, Valainis GT, Godenick MT, Kajdasz DK, Palesch YY. Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: a prospective, double-blind, randomized, placebo-controlled trial. Infect. Dis. Clin. Pract. 2000;9:169-75.

  • 9.

    Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation. 2005;80:868-71. [PubMed ID: 16210978].

  • 10.

    Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin. Infect. Dis. 1992;14:S148-S53. [PubMed ID: 1562688].

  • 11.

    Vazquez JA, Sobel JD. Mucosal candidiasis. Infect. Dis. Clin. N Am. 2002;16:793-820.

  • 12.

    Kaufman DA. Prevention of invasive Candida infections in preterm infants: the time is now. Expert Rev. Anti Infect. Ther. 2008;6:393-9. [PubMed ID: 18662105].

  • 13.

    Tscherner M, Schwarzmüller T, Kuchler K. Pathogenesis and antifungal drug resistance of the human fungal pathogen Candida glabrata. Pharmaceuticals. 2011;4:169-86.

  • 14.

    Abranches P, Varejão E, da Silva C, de Fátima Â, Magalhães T, da Silva D, de Resende-Stoianoff M, Reis S, Nascimento C, de Almeida W. Complexes of fluconazole with sodium p-sulfonatocalix [n] arenes: characterization, solubility and antifungal activity. RSC Adv. 2015;5:44317-25.

  • 15.

    Charlier C, Hart E, Lefort A, Ribaud P, Dromer F, Denning D, Lortholary O. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J. Antimicrob. Chemother. 2006;57:384-410.

  • 16.

    Löffler J, Kelly SL, Hebart H, Schumacher U, Lass-Flörl C, Einsele H. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol. Lett. 1997;151:263-68. [PubMed ID: 9228762].

  • 17.

    Sabatelli F, Patel R, Mann P, Mendrick C, Norris C, Hare R, Loebenberg D, Black T, McNicholas P. In-vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 2006;50:2009-15. [PubMed ID: 16723559].

  • 18.

    Déry M, Hasbun R. Fluconazole-resistant Candida: mechanisms and risk factor identification. Curr. Fungal Infect. Rep. 2011;5:23-8.

  • 19.

    Arndt CA, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J. Infect. Dis. 1988;157:178-80. [PubMed ID: 2826606].

  • 20.

    Brammer K, Farrow P, Faulkner J. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 1990;12:S318-S26. [PubMed ID: 2184510].

  • 21.

    Lashof AO, De Bock R, Herbrecht R, De Pauw BE, Krcmery V, Aoun M, Akova M, Cohen J, Siffnerova H, Egyed M, Ellis M. An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. Eur. J. Cancer. 2004;40:1314-9. [PubMed ID: 15177489].

  • 22.

    Epstein JB, Gorsky M, Caldwell J. Fluconazole mouthrinses for oral candidiasis in postirradiation, transplant, and other patients. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2002;93:671-5. [PubMed ID: 12142873].

  • 23.

    Goins RA, Ascher D, Waecker N, Arnold J, Moorefield E. Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants. Pediatr. Infect. Dis. J. 2002;21:1165-7. [PubMed ID: 12506950].

  • 24.

    Lefebvre JL, Domenge C. A comparative study of the efficacy and safety of fluconazole oral suspension and amphotericin B oral suspension in cancer patients with mucositis. Oral Oncol. 2002;38:337-42. [PubMed ID: 12076696].

  • 25.

    Sholapurkar A, Pai KM, Rao S. Comparison of efficacy of fluconazole mouthrinse and clotrimazole mouthpaint in the treatment of oral candidiasis. Aust. Dent. J. 2009;54:341-6. [PubMed ID: 20415933].

  • 26.

    Taillandier J, Esnault Y, Alemanni M. A comparison of fluconazole oral suspension and amphotericin B oral suspension in older patients with oropharyngeal candidosis. Multicentre Study Group. Age Ageing. 2000;29:117-23. [PubMed ID: 10791445].

  • 27.

    Koks C, Crommentuyn K, Mathot R, Mulder J, Meenhorst P, Beijnen J. Prognostic factors for the clinical effectiveness of fluconazole in the treatment of oral candidiasis in HIV-1-infected individuals. Pharmacol. Res. 2002;46:89-94. [PubMed ID: 12208126].

  • 28.

    Lyon JP, de Resende MA. Correlation between adhesion, enzyme production, and susceptibility to fluconazole in Candida albicans obtained from denture wearers. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2006;102:632-8. [PubMed ID: 17052640].

  • 29.

    Meberg A, Langslet A, Søvde A, Kolstad A. Candida-septicemia with chorioretinitis, osteomyelitis and arthritis treated with systemic miconazole and intraarticular amphotericin B. Mycoses. 1977;20:257-60.

  • 30.

    Tang C. Successful treatment of Candida albicans osteomyelitis with fluconazole. J. Infect. 1993;26:89-92. [PubMed ID: 8454893].

  • 31.

    Albengres E, Le Louët H, Tillement JP. Systemic antifungal agents. Drug Saf. 1998;18:83-97. [PubMed ID: 9512916].

  • 32.

    Denning DW, Venkateswarlu K, Oakley KL, Anderson M, Manning N, Stevens DA, Warnock DW, Kelly SL. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 1997;41:1364-8. [PubMed ID: 9174200].

  • 33.

    Hoffman HL, Ernst EJ, Klepser ME. Novel triazole antifungal agents. Expert Opin. Investig. Drugs. 2000;9:593-605.

  • 34.

    Livermore D. The need for new antibiotics. Clin. Microbiol. Infect. 2004;10:1-9.

  • 35.

    Meis JF, Verweij PE. Current management of fungal infections. Drugs. 2001;61:13-25. [PubMed ID: 11219547].

  • 36.

    Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhäuser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 1998;42:3065-72. [PubMed ID: 9835492].

  • 37.

    Orozco AS, Higginbotham LM, Hitchcock CA, Parkinson T, Falconer D, Ibrahim AS, Ghannoum MA, Filler SG. Mechanism of Fluconazole Resistance in Candida krusei. Antimicrob. Agents Chemother. 1998;42:2645-49. [PubMed ID: 9756770].

  • 38.

    Parkinson T, Falconer D, Hitchcock C. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob. Agents Chemother. 1995;39:1696-9. [PubMed ID: 7486903].

  • 39.

    Redding SW, Kirkpatrick WR, Saville S, Coco BJ, White W, Fothergill A, Rinaldi M, Eng T, Patterson TF, Lopez-Ribot J. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J. Clin. Microbiol. 2003;41:619-22. [PubMed ID: 12574256].

  • 40.

    Ali M, Ahmed M, Ahmed S, Ali SI, Perveen S, Mumtaz M, Haider SM, Nazim U. Fluconazole and its interaction with metal (II) complexes: SEM, spectroscopic and antifungal studies. Pak. J. Pharma. Sci. 2017;30:187-94.

  • 41.

    Zhang CX, Lippard SJ. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol. 2003;7:481-9. [PubMed ID: 12941423].

  • 42.

    Desai SR, Dharwadkar SR. Study of process induced polymorphic transformations in fluconazole drug. Acta Pol. Pharm. 2009;66:115-22. [PubMed ID: 19719043].

  • 43.

    Al-Saif FA, Refat MS. Synthesis, spectroscopic, and thermal investigation of transition and non-transition complexes of metformin as potential insulin-mimetic agents. J. Therm. Anal. Calorim. 2013;111:2079-96.

  • 44.

    Zhou CH, Zhang YY, Yan CY, Wan K, Gan LL, Shi Y. Recent researches in metal supramolecular complexes as anticancer agents. Anticancer Agents Med. Chem. 2010;10:371-95. [PubMed ID: 20380632].

  • 45.

    Moura EA, Correia LP, Pinto MF, Procópio JVV, de Souza FS, Macedo RO. Thermal characterization of the solid state and raw material fluconazole by thermal analysis and pyrolysis coupled to GC/MS. J. Therm. Anal. Calorim. 2010;100:289-93.

  • 46.

    Park HJ, Kim MS, Lee S, Kim JS, Woo JS, Park JS, Hwang SJ. Recrystallization of fluconazole using the supercritical antisolvent (SAS) process. Int. J. Pharm. 2007;328:152-60. [PubMed ID: 16959448].

  • 47.

    Caira MR, Alkhamis KA, Obaidat RM. Preparation and crystal characterization of a polymorph, a monohydrate, and an ethyl acetate solvate of the antifungal fluconazole. J. Pharm. Sci. 2004;93:601-11. [PubMed ID: 14762899].

  • 48.

    Herchel R, Šindelář Z, Trávníček Z, Zbořil R, Vančo J. Novel 1D chain Fe (III)-salen-like complexes involving anionic heterocyclic N-donor ligands Synthesis X-ray structure magnetic 57Fe Mössbauer and biological activity studies. Dalton Trans. 2009;2009:9870-80.

  • 49.

    Li SL, Lan YQ, Ma JF, Yang J, Wang XH, Su ZM. Syntheses and structures of organic−inorganic hybrid compounds based on metal-fluconazole coordination polymers and the β-Mo8O26 anion. Inorg. Chem. 2007;46:8283-90. [PubMed ID: 17824699].

  • 50.

    Pansuriya PB, Patel MN. Synthesis, characterization and biological aspects of novel five-coordinated dimeric-Cu (II) systems. J. Enzyme Inhib. Med. Chem. 2008;23:108-19. [PubMed ID: 18341262].

  • 51.

    Ren Y, Zhang L, Zhou CH, Geng R. Recent development of benzotriazole-based medicinal drugs. Med. Chem. 2014;4:640-62.